PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG Global Network Study (EORTC 62072).
W. T. Van Der Graaf
No relevant relationships to disclose
J. Blay
Consultant or Advisory Role - GlaxoSmithKline (U)
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
S. P. Chawla
No relevant relationships to disclose
D. Kim
Consultant or Advisory Role - MEK
B. Bui Nguyen
No relevant relationships to disclose
P. G. Casali
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Novartis; Pfizer; PharmaMar
Research Funding - GlaxoSmithKline
Other Remuneration - Pfizer; PharmaMar
P. Schöffski
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
M. Aglietta
No relevant relationships to disclose
A. P. Staddon
Research Funding - GlaxoSmithKline
Y. Beppu
No relevant relationships to disclose
A. Le Cesne
Consultant or Advisory Role - Novartis; Pfizer; PharmaMar
Honoraria - Novartis; Pfizer; PharmaMar
H. Gelderblom
No relevant relationships to disclose
I. R. Judson
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
N. Araki
No relevant relationships to disclose
M. Ouali
No relevant relationships to disclose
S. Marreaud
No relevant relationships to disclose
R. Hodge
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
M. Dewji
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
A. P. Dei Tos
No relevant relationships to disclose
P. Hohenberger
No relevant relationships to disclose